MarketCap
Facebook
X
Telegram
Ocular Therapeutix Net Income | OCUL
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Ocular Therapeutix
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -266 M | -194 M | -80.7 M | -71 M | -6.55 M | -156 M | -86.4 M | -60 M | -63.4 M | -44.7 M | -39.7 M | -28.6 M | -13.3 M | -14.1 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.55 M | -266 M | -80.3 M |
Quarterly Net Income Ocular Therapeutix
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -88.6 M | - | -69.4 M | -67.8 M | -64.1 M | - | -36.5 M | -43.8 M | -64.8 M | - | -516 K | -20.7 M | -30.3 M | - | -24.2 M | -18.8 M | -12.5 M | - | 2.66 M | -8.48 M | 3.12 M | - | -11.9 M | -36.6 M | -21.5 M | -26 M | -18.8 M | -24.5 M | -17.1 M | -17.4 M | -15 M | -13.8 M | -13.8 M | -13.1 M | -15.6 M | -18.7 M | -16 M | -12.8 M | -9.6 M | -11.4 M | -10.8 M | -10.6 M | -11.5 M | -10 M | -7.58 M | -7.95 M | -7.29 M | -6.39 M | -7.01 M | -3.5 M | -3.52 M | -3.09 M | -3.2 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.12 M | -88.6 M | -20.2 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-27 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Happiness Biotech Group Limited
HAPP
|
-7.89 M | - | 1.35 % | $ 17.8 M |  China |
 |
Dynavax Technologies Corporation
DVAX
|
27.3 M | - | - | $ 2.02 B |  USA |
 |
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M | China |
 |
Corner Growth Acquisition Corp.
COOL
|
-322 K | - | -0.89 % | $ 114 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-195 M | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17 M | - | -13.47 % | $ 169 M | France |
 |
Alpine Immune Sciences
ALPN
|
-32.2 M | - | - | $ 2.17 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-44.2 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
AstraZeneca PLC
AZN
|
10.2 B | - | - | $ 96.9 B |  Britain |
 |
CureVac N.V.
CVAC
|
162 M | - | - | $ 867 M |  Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-106 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-40 M | - | 0.74 % | $ 768 M |  Israel |
 |
Abcam plc
ABCM
|
-8.5 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
149 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.38 M | - | -18.52 % | $ 27.3 M | Britain |
 |
MorphoSys AG
MOR
|
-190 M | - | 2.43 % | $ 254 M | Germany |
 |
Geron Corporation
GERN
|
-83.5 M | $ 1.42 | -2.07 % | $ 947 M | USA |
 |
Affimed N.V.
AFMD
|
-106 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.4 M | - | - | $ 231 M | USA |
 |
Inhibikase Therapeutics
IKT
|
-48.3 M | $ 2.33 | - | $ 229 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-102 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
-40.9 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-98 M | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
-132 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-38 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
3 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-89 M | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
-608 M | - | - | $ 3.37 B | China |
 |
Jaguar Health
JAGX
|
-54 K | $ 0.96 | -6.48 % | $ 2.24 M | USA |
 |
Johnson & Johnson
JNJ
|
26.8 B | $ 263.4 | 1.58 % | $ 634 B | USA |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.4 M | - | 5.93 % | $ 314 M | Canada |
 |
Alkermes plc
ALKS
|
242 M | $ 52.89 | -0.15 % | $ 8.71 B |  Irlanda |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
Achieve Life Sciences
ACHV
|
-54.6 M | $ 6.1 | -1.13 % | $ 266 M | USA |
 |
AIkido Pharma
AIKI
|
-22.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
-25.5 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-64.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-43.4 M | - | 4.14 % | $ 49.1 M | USA |